MA El-Barrawy

MA El-Barrawy

Alexandria University, Egypt

Title: Comparative immunohistochemical analysis of beclin-1 & mdm-2 in benign & malignant ameloblastomas


MA El-Barrawy post doctoral fellow of M.D. Anderson Cancer & Tumor Institute, Texas University (Houston, USA): October 1988-April 1989 and currently teaching and supervising postgraduate Physicians, Pharmacists, Chemists, and Veterinarians enrolled at HIPH, Alex. University, to get their postgraduate degree. Having experience in various investigations of: Microbiology (Bacteriology, Virology and Mycology), Immunology, Clinical Pathology, Histocompatibility, and field surveys .


Ameloblastoma is the most frequently encountered neoplasm arising from the odontogenic epithelium. Beclin 1 protein plays a critical role in autophagy as a tumor suppressor gene. Whereas, the Murine Double Minute 2 (MDM 2) is a cellular proto-oncogene capable, if amplified, of causing tumor-genesis. The expression & prognostic significance of both genes are largely unexplored, yet, in this neoplasia. Therefore, the present investigation aimed to assess their possible biological role in ameloblastomas. Methods: This study was done among 35 studied cases: 29 cases of benign ameloblastomas, and 6 cases of ameloblastic carcinomas. Labeled Streptavidin Biotin (LSAB + Dako) immunohistochemical method, utilizing monoclonal antibodies for Beclin 1 & MDM 2 genes, was used. Results: Most of the benign ameloblastomas showed intense total cell positivity for the Beclin 1, while, the ameloblastic carcinomas revealed mild to negative expression. Inversely, the MDM 2 oncoprotein demonstrated intense brown total cell reactivity in amelobastic carcinoma & loss of the reaction to mild brown stain in benign ameloblastoma. Conclusion: Based from these findings, one could conclude that, MDM 2 could be a specific marker to identify the proliferative activity, tumor aggressiveness & directly proportional with the degree of malignancy. In contrast, the high Beclin 1 expression could be a good indicator of prognosis in ameloblastomas. Hence, an overall comparison, both studied genes may be very promising molecular prognostic biomarkers.